8 results about "Supporting cell" patented technology

Featured are methods, compositions, and apparatuses for the in vitro maturation of oocytes. In particular, the disclosure features methods of inducing oocyte maturation in vitro, by co-culturing a female subject's oocytes with an ex vivo composition containing a plurality of ovarian support cells (e.g., granulosa cells). Additional methods for administering follicular triggering agents and retrieving oocytes from the female subject are provided. Such methods, compositions, and apparatuses are particularly useful for assisted reproduction technology (ART) procedures.

The application belongs to the field of biomedical models and gene engineering technologies, and relates to a large vestibular aqueduct syndrome animal model construction method and application. SLC26A4 The application adopts CRISPR / Cas9 gene editing technology to mutate a gene c.707T>C, so as to construct a genotype-confirmed SLC26A4 Mutant animal model, and through inner ear high-resolution imaging evaluation, longitudinal hearing physiological function monitoring and inner ear tissue molecular pathology analysis, it is confirmed that the model can stably reproduce the core phenotypes of human large vestibular aqueduct syndrome, including significant vestibular aqueduct and endolymphatic sac expansion, progressive hearing threshold increase and secondary damage of cochlear hair cells and supporting cells.

Prosthetic heart valves including a radially expandable annular frame and valvular structure disposed within the frame, as well as methods and delivery apparatus associated therewith, are disclosed. The frame can include commissure-supporting cells for attachment of commissures of the valvular structure to the frame. The commissure-supporting cells can be offset from an outflow end of the frame by an offset distance and aligned with gaps in the frame. In some examples, the gaps are defined by a row of discontinuous cells in an outflow portion of the frame. In some examples, the gaps are defined by pairs of cells in an outflow portion of the frame. In some examples, the pairs of cells are enlarged relative to other cell of the frame.

This invention provides a method to improve age-related decline in ovarian function by supplementing quiescent oocytes within primordial follicles. [Solution] The present invention provides a method for inducing mature oocytes, comprising the steps of: preparing a single-cell suspension from the ovary of a mammal other than a human; separating the single-cell suspension into oocytes and ovarian somatic cells (supporting cells) within a primordial follicle using a flow cytometer; re-aggregating the oocytes and ovarian somatic cells within the separated primordial follicle; and maturing the re-aggregated primordial follicle in vitro.

The application belongs to the technical field of gene therapy, and particularly relates to an AAV capsid protein mutant targeting glial cells and application thereof. The AAV capsid protein mutant is constructed by inserting a polypeptide with glial cell infection characteristics between N589 and R590 of an AAV-DJ capsid protein amino acid sequence, and exhibits enhanced transduction and targeting in inner ear basal membrane supporting cells, and has the function of enhancing supporting cell transduction in the cochlear basal membrane of newborn and adult mice, thereby being capable of solving the problem of low transduction efficiency of AAV in the cochlear basal membrane supporting cells of adult mice, and providing a potentially available tool for gene therapy of deafness genes positioned in supporting cells by Chen et al. GJB2 and the like.

This invention relates to the fields of environmental toxicology and organoid technology, and particularly to a method for assessing the toxicity of environmental microplastic exposure based on testicular organoids. The method includes: processing waste testicular tissue into a single-cell suspension, the single-cell suspension comprising supporting cells, germ cells, and interstitial cells; seeding the single-cell suspension onto a biomimetic hydrogel scaffold for culture to obtain mature testicular organoids, which are then cultured in a target microplastic exposure solution to establish a microplastic exposure model; determining the raw values ​​of toxicity assessment indicators corresponding to the microplastic exposure model, including: morphological score data, grayscale values ​​of cell marker expression, DNA damage indicators, testosterone secretion levels, and cytotoxicity indicators; calculating a comprehensive toxicity score based on the raw values ​​of each toxicity assessment indicator, and assessing the reproductive toxicity risk level of the target microplastic exposure based on the comprehensive toxicity score. This application can improve the accuracy of assessing the reproductive toxicity risk level of microplastic exposure.

This invention provides a method for isolating and identifying interstitial cells from Bactrian camels, belonging to the field of cell isolation technology. A mixture of 0.08–0.12% collagenase IV solution and 0.23–0.27% trypsin-EDTA at a volume ratio of 1:2 is used to digest Bactrian camel testicular tissue blocks. The mixture is then purified by hypotonic treatment to remove excess germ cells, differential adhesion purification to remove a large number of supporting cells, and Percoll density gradient centrifugation to remove a small number of supporting cells. The suspension, obtained from a 34%–60% Percoll gradient, is transferred to a new culture flask to obtain interstitial cells with a purity ≥95%. Identification is performed using morphological observation, immunofluorescence staining, and secretory function testing. The interstitial cells isolated from Bactrian camels using this invention can be used for research on the reproductive performance of Bactrian camels, laying the foundation for understanding the reproductive performance of Bactrian camels.

This invention provides a composition for treating ovarian insufficiency (POF) and its application. The composition comprises two synergistic modules: first, hiPSC-derived ovarian support cells (iPSC-OSCs) pre-adapted to FTY720 and possessing enhanced oxidative stress tolerance; second, reactive oxygen species (ROS)-responsive dual-targeting lipid nanoparticles (RRDT-LNPs) loaded with a therapeutic agent (such as urestatin A). The RRDT-LNPs are functionalized from a ROS-responsive material containing a thioketal (TK) linker, a primary targeting peptide CNGRC, and a secondary dual-targeting fusion protein VHH-FP. This invention also provides a method for the directed differentiation and pre-adaptation of the iPSC-OSCs, and a method for preparing the RRDT-LNPs. In vitro and in vivo experiments have demonstrated that the composition of this invention, through the organic combination of "cell empowerment" and "intelligent targeted drug delivery," can sequentially activate targeting capabilities in the pathological microenvironment, efficiently repairing ovarian function, restoring endocrine levels, and exhibiting good safety, providing a novel synergistic treatment option for POF.